Before revision: The idea behind the directive was that no medicinal product should ever again be marketed in the European Union without prior authorisation , thereby diminishing potential side effects
After revision: The directive aimed at harmonising standards for the approval of medicines within the then European Economic Community and required that medicines could not be marketed within the community without prior authorisation of the competent authority of at least one member state